Related Experiment Videos
Prospects for a group A streptococcal vaccine
David J McMillan1, Gursharan S Chhatwal
1GBF-German Research Center for Biotechnology, Department of Microbial Pathogenesis and Vaccine Research, Division of Microbiology, Braunschweig, Germany. dmc@gbf.de
Current Opinion in Molecular Therapeutics
|March 1, 2005
Summary
Developing a Group A Streptococcus (GAS) vaccine is crucial due to rising severe infections and disease burden. Research is exploring novel vaccine candidates beyond the traditional M protein.
Area of Science:
- Microbiology
- Vaccinology
- Infectious Diseases
Background:
- Group A Streptococcus (GAS) causes significant human diseases like pharyngitis, impetigo, and rheumatic heart disease.
- Severe GAS infections are increasing in Western countries, with a high burden in developing nations despite antibiotic availability.
Purpose of the Study:
- To address the need for a safe and effective Group A Streptococcus (GAS) vaccine.
- To investigate novel vaccine candidates beyond the established M protein.
Main Methods:
- Review of published Group A Streptococcus (GAS) genomes.
- Identification and investigation of non-M protein vaccine candidates.
Main Results:
- Several GAS genomes have been published, providing new insights.
- A number of non-M protein vaccine candidates are now under investigation.
Conclusions:
- The increasing incidence and burden of GAS infections necessitate vaccine development.
- Exploration of non-M protein targets offers promising avenues for a new GAS vaccine.